Trial reportThe European respiratory journal2014
Prednisone in COPD exacerbation requiring ventilatory support: an open-label randomised evaluation.
Trial report in The European respiratory journal, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 6 syntheses or guidelines pooled it, 81 citations in OpenAlex.
- Role of systemic corticosteroids in ventilated patients with chronic obstructive pulmonary disease exacerbation: a systematic review and meta-analysis.BMC pulmonary medicine · 2026Pooled it
- Glucocorticoid treatment and new-onset hyperglycaemia and diabetes in people living with chronic obstructive pulmonary disease: A systematic review and meta-analysis.Diabetic medicine : a journal of the British Diabetic Association · 2025Pooled it
- Metabolic adverse events associated with systemic corticosteroid therapy-a systematic review and meta-analysis.BMJ open · 2022Pooled it
- Different durations of corticosteroid therapy for exacerbations of chronic obstructive pulmonary disease.The Cochrane database of systematic reviews · 2018Pooled it
- Glucocorticoid-induced hyperglycaemia in respiratory disease: a systematic review and meta-analysis.Diabetes, obesity & metabolism · 2016Pooled it
- Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease.The Cochrane database of systematic reviews · 2014Pooled it
- Management of Asthma and COPD Exacerbations in Adults in the ICU.CHEST critical care · 2025Article
- Oral Corticosteroid-Related Healthcare Resource Utilization and Associated Costs in Patients with COPD.Advances in therapy · 2025Observational
- Article
- A Review of Current Evidence for the Use of Steroids in the Medical Intensive Care Unit.Diagnostics (Basel, Switzerland) · 2024Review
- Early and late effects of volatile sedation with sevoflurane on respiratory mechanics of critically ill COPD patients.Annals of intensive care · 2024Article
- Assessment of phosphatemia at admission to the intensive care unit to predict mechanical ventilation among patients with acute exacerbation of chronic obstructive pulmonary disease: a retrospective cohort study.Annals of translational medicine · 2024Article
- Respiratory Infection Triggering Severe Acute Exacerbations of Chronic Obstructive Pulmonary Disease.International journal of chronic obstructive pulmonary disease · 2024Article
- Randomized Controlled Trials on Chronic Obstructive Pulmonary Disease in Africa: A Systematic Review.Chronic obstructive pulmonary diseases (Miami, Fla.) · 2023Article
- Article
- A Long-Term Study of Adverse Outcomes Associated With Oral Corticosteroid Use in COPD.International journal of chronic obstructive pulmonary disease · 2023Observational
- Article
- Rationale and design of REGULATE: an observational study protocol for relationship between plasma metabolome and the efficacy of systemic glucocorticoid in acute exacerbation of chronic obstructive pulmonary disease.BMC pulmonary medicine · 2021Observational
- Article
- Low skeletal muscle area as a prognostic marker for chronic obstructive pulmonary disease in elderly patients admitted to ICU.Scientific reports · 2019Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recommendation of the use of systemic steroids in chronic obstructive disease (COPD) exacerbation rely on trials that excluded patients requiring ventilatory support. In an open-label, randomised evaluation of oral prednisone administration, 217 patients with acute COPD exacerbation requiring ventilatory support were randomised (with stratification on the type of ventilation) to usual care (n=106) or to receive a daily dose of prednisone (1 mg·kg(-1)) for up to 10 days (n=111). There was no difference regarding the primary end-point, intensive care unit mortality, which was 17 (15.3%) deaths versus 15 (14%) deaths in the steroid-treated and control groups, respectively (relative risk 1.08, 95% CI 0.6-2.05). Analysis according to ventilation modalities showed similar mortality rates. Noninvasive ventilation failed in 15.7% and 12.7% (relative risk 1.25, 95% CI 0.56-2.8; p=0.59), respectively. Both study groups had similar median mechanical ventilation duration and intensive care unit length of stay, which were 6 (interquartile range 6-12) days versus 6 (3.8-12) days and 9 (6-14) days versus 8 (6-14) days, respectively. Hyperglycaemic episodes requiring initiation or alteration of current insulin doses occurred in 55 (49.5%) patients versus 35 (33%) patients in the prednisone and control groups, respectively (relative risk 1.5, 95% CI 1.08-2.08; p=0.015). Prednisone did not improve intensive care unit mortality or patient-centred outcomes in the selected subgroup of COPD patients with severe exacerbation but significantly increased the risk of hyperglycaemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.